Investing Strategies

April 05, 2019

Buy ($175)

Companies covered: Micron Technology, Inc. (NASDAQ:MU), Avery Dennison Corporation (NYSE:AVY), Entergy Corporation (NYSE:ETR), Amazon.com, Inc. (NASDAQ:AMZN), Wal-Mart Stores, Inc. (NYSE:WMT), Target Corporation (NYSE:TGT), Microsoft Corporation (NASDAQ:MSFT), Intel Corporation (NASDAQ:INTC), Federal Realty Investment Trust (NYSE:FRT), First Hawaiian (NASDAQ:FHB), Walt Disney Company (The) (NYSE:DIS), Sherwin-Williams Company (The) (NYSE:SHW), Lowe's Companies, Inc. (NYSE:LOW), Home Depot, Inc. (The) (NYSE:HD), BNP Paribas (ADR) (OTCMKTS:BNPQY), Lenovo Group Limited (HKG:0992), International Business Machines Corporation (NYSE:IBM), Hewlett Packard Enterprise Co (NYSE:HPE), Huawei Culture Co. Ltd. (SHE:002502), Apple Inc. (NASDAQ:AAPL), Samsung Electronics Co Ltd (KRX:005930), Huadian Power International (HKG:1071), China Resources Power Holdings Co. Ltd. (HKG:0836), Alphabet Inc (NASDAQ:GOOG), ServiceNow, Inc. (NYSE:NOW), HP Inc (NYSE:HPQ), Accenture plc. (NYSE:ACN), Zendesk Inc (NYSE:ZEN), Salesforce.com Inc (NYSE:CRM), Workday, Inc. (NYSE:WDAY), Oracle Corporation (NYSE:ORCL), SAP SE (NYSE:SAP), Mastercard Incorporated (NYSE:MA), Visa Inc. (NYSE:V), Paypal Holdings Inc (NASDAQ:PYPL), Facebook, Inc. (NASDAQ:FB), Netflix, Inc. (NASDAQ:NFLX), American Eagle Outfitters, Inc. (NYSE:AEO), New York Times Company (The) (NYSE:NYT), BillerudKorsnas AB (OTCMKTS:BLRDF), Tomra Systems ASA (ADR) (OTCMKTS:TMRAY)

Recreation and Leisure

April 05, 2019

Buy ($175)

Companies covered: Spark Networks, Inc. (NYSEAMERICAN:LOV), The Meet Group, Inc. (NASDAQ:MEET), Cinedigm Corp (NASDAQ:CIDM), Netflix, Inc. (NASDAQ:NFLX), Amazon.com, Inc. (NASDAQ:AMZN), Apple Inc. (NASDAQ:AAPL), Facebook, Inc. (NASDAQ:FB), Twitter, Inc. (NYSE:TWTR), Walt Disney Company (The) (NYSE:DIS), Viacom Inc. (NASDAQ:VIA), Sinclair Broadcast Group, Inc. (NASDAQ:SBGI), Dolphin Entertainment (NASDAQ:DLPN), Match Group (NASDAQ:MTCH), Alphabet Inc (NASDAQ:GOOG), eBay Inc. (NASDAQ:EBAY), Expedia, Inc. (NASDAQ:EXPE), Ctrip.com International, Ltd. (NASDAQ:CTRP), Booking Holdings (NASDAQ:BKNG), Meituan Dianping (OTCMKTS:MPNGF), Eldorado Resorts, Inc. (NASDAQ:ERI), Caesars Entertainment Corporation (NASDAQ:CZR), International Game Technology (NYSE:IGT), IMAX Corporation (NYSE:IMAX), AMC Entertainment Holdings, Inc. (NYSE:AMC), Hilton Hotels Corporation Common Stock (NYSE:HLT), Marriott International (NASDAQ:MAR), Hyatt Hotels Corporation (NYSE:H), Golden Entertainment Inc (NASDAQ:GDEN), Wynn Resorts, Limited (NASDAQ:WYNN), The Stars Group (NASDAQ:TSG), GW Pharmaceuticals Plc (NASDAQ:GWPH), Constellation Brands Inc (NYSE:STZ), Canopy Growth Corp. (NYSE:CGC), Altria Group (NYSE:MO), Cronos Group (NASDAQ:CRON), Tilray (NASDAQ:TLRY), Novartis AG (NYSE:NVS), CannTrust Holdings Inc. (NYSE:CTST), Thermo Fisher Scientific Inc (NYSE:TMO), Valens GroWorks Corp. (OTCMKTS:VGWCF), Auxly Cannabis Group (OTCMKTS:CBWTF), McDonald's Corporation (NYSE:MCD), Starbucks Corporation (NASDAQ:SBUX), Yum! Brands, Inc. (NYSE:YUM), Restaurant Brands International Inc. (NYSE:QSR), BJ's Restaurants Inc. (NASDAQ:BJRI), Dine Brands Global (NYSE:DIN), Dunkin' Brands Group, Inc. (NASDAQ:DNKN), GrubHub Inc. (NYSE:GRUB), Chipotle Mexican Grill, Inc. (NYSE:CMG), Darden Restaurants, Inc. (NYSE:DRI), Molson Coors Brewing Company (NYSE:TAP), Acreage Holdings (OTCMKTS:ACRGF), Curaleaf Holdings (OTCMKTS:CURLF), Green Thumb Industries (OTCMKTS:GTBIF), HEXO Corp. (NYSEAMERICAN:HEXO), Celsius Holdings, Inc. (NASDAQ:CELH), Red Lion Hotels Corporation (NYSE:RLH), Grown Rogue International Inc. (CNSX:GRIN)

Investing Strategies

March 22, 2019

Buy ($175)

Companies covered: Boeing Company (The) (NYSE:BA), Airbus SE (OTCMKTS:EADSY), Broadcom Ltd (NASDAQ:AVGO), Analog Devices, Inc. (NASDAQ:ADI), Royal Caribbean Cruises Ltd. (NYSE:RCL), Alphabet Inc (NASDAQ:GOOG), JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), Exxon Mobil Corporation (NYSE:XOM), Facebook, Inc. (NASDAQ:FB), Phillips 66 (NYSE:PSX), ConocoPhillips (NYSE:COP), Toronto Dominion Bank (The) (NYSE:TD), General Electric Company (NYSE:GE)

Proprietary Genome Editing Platforms

March 22, 2019

Buy ($175)

Companies covered: Celyad SA (ADR) (NASDAQ:CYAD), bluebird bio, Inc. (NASDAQ:BLUE), Spark Therapeutics, Inc. (NASDAQ:ONCE), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Rocket Pharmaceuticals (NASDAQ:RCKT), Biogen Inc. (NASDAQ:BIIB), Ionis Pharmaceuticals Inc (NASDAQ:IONS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Pfizer, Inc. (NYSE:PFE), Abeona Therapeutics (NASDAQ:ABEO), LogicBio Therapeutics (NASDAQ:LOGC), Krystal Biotech (NASDAQ:KRYS), Global Blood Therapeutics (NASDAQ:GBT), Lonza Group AG (ADR) (OTCMKTS:LZAGY), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Celgene Corporation (NASDAQ:CELG), Bristol-Myers Squibb Company (NYSE:BMY), uniQure N.V. (NASDAQ:QURE), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), CRISPR Therapeutics AG (NASDAQ:CRSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Voyager Therapeutics (NASDAQ:VYGR), Lysogene SA (EPA:LYS), Nightstar Therapeutics PLC (NASDAQ:NITE), Denali Therapeutics (NASDAQ:DNLI), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Bio-Path Holdings, Inc. (NASDAQ:BPTH), Regenxbio Inc (NASDAQ:RGNX), PTC Therapeutics, Inc. (NASDAQ:PTCT), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Axovant Sciences Ltd. (NASDAQ:AXGT), Ophthotech Corporation (NASDAQ:OPHT), MeiraGTx Holdings PLC (NASDAQ:MGTX), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Illumina, Inc. (NASDAQ:ILMN), Amazon.com, Inc. (NASDAQ:AMZN), Cellectis S.A. (NASDAQ:CLLS), AquaBounty Technologies, Inc. (NASDAQ:AQB), Biocon Ltd. (BOM:532523), Invitae Corp. (NYSE:NVTA)

Biotechnology and Pharmaceuticals

March 15, 2019

Buy ($175)

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), bluebird bio, Inc. (NASDAQ:BLUE), ProQR Therapeutics N.V. (NASDAQ:PRQR), Intellia Therapeutics (NASDAQ:NTLA), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), InflaRx NV (NASDAQ:IFRX), ChemoCentryx, Inc. (NASDAQ:CCXI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Celgene Corporation (NASDAQ:CELG), VBI Vaccines Inc. (NASDAQ:VBIV), Acer Therapeutics (NASDAQ:ACER), SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Proteon Therapeutics, Inc. (NASDAQ:PRTO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Chiasma (NASDAQ:CHMA), Veru (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Medicenna Therapeutics Corp. (OTCMKTS:MDNAF), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Wave Life Sciences Ltd (NASDAQ:WVE), Merck & Company, Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Pfizer, Inc. (NYSE:PFE), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), MacroGenics, Inc. (NASDAQ:MGNX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Astrazeneca PLC (NYSE:AZN), Novartis AG (NYSE:NVS), Strongbridge Biopharma plc (NASDAQ:SBBP), Moderna (NASDAQ:MRNA), Spark Therapeutics, Inc. (NASDAQ:ONCE), Mustang Bio, Inc. (NASDAQ:MBIO), CEL-SCI Corporation (NYSEAMERICAN:CVM), Eli Lilly and Company (NYSE:LLY), vTv Therapeutics Inc (NASDAQ:VTVT), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ProMIS Neurosciences (TSE:PMN), BioPorto A/S (CPH:BIOPOR), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), True Leaf Medicine International Ltd. (OTCMKTS:TRLFF), Auris Medical Holding AG (NASDAQ:EARS), Cellectis S.A. (NASDAQ:CLLS), Celyad SA (ADR) (NASDAQ:CYAD), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), T2 Biosystems, Inc. (NASDAQ:TTOO), Nightstar Therapeutics PLC (NASDAQ:NITE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Blueprint Medicines Corp. (NASDAQ:BPMC), Genocea Biosciences, Inc. (NASDAQ:GNCA), Bristol-Myers Squibb Company (NYSE:BMY), Verastem, Inc. (NASDAQ:VSTM), Bayer AG (ADR) (OTCMKTS:BAYRY), Clovis Oncology, Inc. (NASDAQ:CLVS), Deciphera Pharmaceuticals (NASDAQ:DCPH), BerGenBio ASA (FRA:7BG), Forty Seven (NASDAQ:FTSV), Neon Therapeutics (NASDAQ:NTGN), Gritstone Oncology (NASDAQ:GRTS), OSE Immunotherapeutics SA (OTCMKTS:ORPOF), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Mesoblast Limited (NASDAQ:MESO), Redhill Biopharma Ltd. (NASDAQ:RDHL), Omeros Corporation (NASDAQ:OMER), ADMA Biologics Inc (NASDAQ:ADMA), DBV Technologies S.A. (NASDAQ:DBVT)

Latest News